Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Kura Oncology, Inc. (NASDAQ: KURA)
KURA Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
91.20%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
219.90%
KURA Stock Analysis
KURA
PE Ratio:
KURA
PEG Ratio:
Not Available
KURA
Forward EPS Growth (12 month):
0.00%
KURA
PS Ratio:
10.7
KURA
PSG Ratio:
0.1
KURA
Forward Revenue Growth (12 month):
104.30%
KURA Articles
No data was found